Irm LLC

Novartis Ag

Opple Lighting Co., Ltd.

Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Recurium IP Holdings, LLC

Suzhou Opple Lighting Co., Ltd.

Guobao Zhang

Shifeng Pan

Pingda Ren

Wenqi Gao

Nathanael Schiander Gray

Qiang Ding

Yi Liu

Tetsuo Uno

Yongping Xie

Bing Li

Feng He

Pamela Ann Albaugh

Weikang Tao

Kevin Duane Bunker

Peter Qinhua Huang

Qiong Zhang

Yongqin Wan

Xing Wang

Sayee Gajanan Hegde

Pascal Furet

Paul William Manley

Guido Bold

Chengzhi Zhang

Paul A Renhowe

Tao Jiang

Lei Zhang

Chao Yan

Daniel J Poon

Martin Sendzik

Marc Lang

Giorgio Caravatti

Vito Guagnano

Shenlin Huang

Werner Breitenstein

Yi Zhang

Qiyue Hu

Pierre-Yves Michellys

Zuosheng Liu

Phillip B Alper

Baogen Wu

Songchun Jiang

Nathanael S Gray

Xia Wang

Dai Cheng

Dong Han

Taebo Sim

Shuli You

Guolong Ni

Jiqing Jiang

Zhanhua Chen

Yun Feng Xie

Hyun Soo Lee

Lintong Li

Ha-Soon Choi

Joseph Schoepfer

Daniel Mutnick

Gregory B Chopiuk

Carsten Spanka

Barun Okram

Wei Pei

Victor Ivanovich Nikulin

Carole Pissot Soldermann

Donghong Zou

Hongwei Chen

Shengjie Qiao

Thomas Knoepfel

Greg Chopiuk

Liangyin Gui

Rajender Reddy Leleti

Jonathan Deane

Nathanel Gray

Guoquan Li

Chunfeng Shu

Dianqiang Ma

Huiqing Yuan

Lichun Shen

Peter Syka

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.

Estrogen receptor modulators

A ceiling lamp and a chassis are provided. The ceiling lamp includes a chassis and a light source module; the chassis includes a surrounding wall and a partition disposed within the surrounding wall, the partition divides a region surrounded by the surrounding wall into an assembly recess with a downward opening and a wiring recess with an upward opening; part of the partition protrudes upwardly into the wiring recess and forms a light source recess with a downward opening and an upward recess bottom, and the light source module is provided in the light source recess. The chassis includes a surrounding wall and a partition disposed within the surrounding wall, the partition divides a region surrounded by the surrounding wall into an assembly recess with a downward opening and a wiring recess with an upwardly opening.

Ceiling lamp and chassis

A hidden fan and a fan lamp are disclosed. The hidden fan includes a turntable assembly and a plurality of fan blade assemblies arranged at the turntable assembly, the turntable assembly has a turntable and a limit wheel configured to rotate relative to the turntable, the turntable has a plurality of fan blade fixing portions, and the plurality of fan blade fixing portions are annularly arranged around a center of the turntable, at least one of the fan blade assemblies has a fan blade and a return elastic component, the fan blade has a fixed portion and a linkage portion arranged at a side of the fixed portion, the fixed portion is arranged at the corresponding fan blade fixing portion, the linkage portion is connected with the limit wheel.

Hidden fan and fan lamp

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer. 

Disclosed are a pyrazolo-heteroaryl derivative, a preparation method and medical use thereof. In particular, this invention relates to a new pyrazolo-heteroaryl derivative as shown in the general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative and the use thereof as a therapeutic agent, in particular as a TLR7 agonist, wherein each substituent in the general formula (I) is defined in the description. 

Pyrazolo-heteroaryl derivative, preparation method and medical use thereof

A heteroaryl-pyrazole derivative, and a preparation method therefor and a medical application thereof are described. Specifically, a new heteroaryl-pyrazole derivative as shown in formula (I), a preparation method for the derivative, a pharmaceutical composition containing the derivative, and a use of the derivative as a therapeutic agent, in particular as a TLR7 agonist, are described. The substituents in formula (I) have the same definitions as in the description. 

Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof

The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases. 

Compounds and compositions as inhibitors of endosomal toll-like receptors

The present disclosure discloses a light source circuit and a lighting device. The light source circuit includes: a substrate, a light source mounted on a surface of the substrate, and an optical element assembled on the substrate; the substrate is provided with a first light source connection region and a second light source connection region; the optical element is provided with a first lens corresponding to the first light source connection region and is provided with a plurality of second lenses corresponding to the second light source connection region; and the light source at least includes a first light source arranged on the first light source connection region.

Optical element, light source circuit and lighting device

The lighting device includes a cover with a receiving chamber defined between a top wall and a side wall extending downwards from the top wall; an insulation component located on an inner surface of the side wall and having a receiving groove; a light source assembly located in the receiving groove; a light guide assembly received in the receiving chamber with an end received in the receiving groove; and a metal frame fixed at a periphery of the cover.

Edge-lit light guide device with light source and light guide end received in receiving groove of cover, and metal frame

The present invention relates to methods for modulating the Wnt signaling pathway using compounds of Formula (1), 

N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators

The present invention relates to compositions and methods for modulating the Wnt signaling pathway.

N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators

The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).

Hedgehog pathway modulators

The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R, R, Rare as defined herein. 

Substituted pyridines for modulating the WNT signaling pathway

The invention relates to compounds of formula (I) wherein the substituents X, R, R, Rand Rhave the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

Compounds and compositions as protein kinase inhibitors

The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A, A, B, Y and Z all represent rings. 

N-(hetero)aryl, 2-(hetero)aryl&#x2014;substituted acetamides for use as Wnt signaling modulators

Growing community of inventors

San Diego, CA, United States of America

Guobao Zhang